Biotech Values

[DewDiligence]

MDT does benefit from The Global Demographic Tailwind…

http://online.wsj.com/article/SB10001424052702303610504577420460420854818.html

Chief Executive Omar Ishrak pointed to new products and the company's growth in emerging markets, where revenue climbed 20% excluding currency fluctuations.

However, I stand by the comments in #msg-72412280 that there are better ways to play TGDT.

MDT uses an fiscal year ending in April, so the results just reported were for FY4Q12. For FY2013, MDT’s guidance is non-GAAP EPS of $3.62-3.70 on revenue growth of 2-4% excluding currency.